HER2-targeted therapy influences CTC status in metastatic breast cancer

Deutsch, Thomas M.; Riethdorf, Sabine; Fremd, Carlo; Feisst, Manuel; Nees, Juliane; Fischer, Chiara; Hartkopf, Andreas D.; Pantel, Klaus; Trumpp, Andreas; Schuetz, Florian; Schneeweiss, Andreas; Wallwiener, Markus

dc.contributor.author	Hartkopf, Andreas
dc.date.accessioned	2020-09-04T13:28:51Z
dc.date.available	2020-09-04T13:28:51Z
dc.date.issued	2020
dc.identifier.issn	1573-7217
dc.identifier.uri	http://hdl.handle.net/10900/106231
dc.language.iso	en	de_DE
dc.publisher	Springer	de_DE
dc.relation.uri	http://dx.doi.org/10.1007/s10549-020-05687-2	de_DE
dc.subject.ddc	610	de_DE
dc.title	HER2-targeted therapy influences CTC status in metastatic breast cancer	de_DE
dc.type	Article	de_DE
utue.quellen.id	20200715072417_00422
utue.publikation.seiten	127-136	de_DE
utue.personen.roh	Deutsch, Thomas M.
utue.personen.roh	Riethdorf, Sabine
utue.personen.roh	Fremd, Carlo
utue.personen.roh	Feisst, Manuel
utue.personen.roh	Nees, Juliane
utue.personen.roh	Fischer, Chiara
utue.personen.roh	Hartkopf, Andreas D.
utue.personen.roh	Pantel, Klaus
utue.personen.roh	Trumpp, Andreas
utue.personen.roh	Schuetz, Florian
utue.personen.roh	Schneeweiss, Andreas
utue.personen.roh	Wallwiener, Markus
dcterms.isPartOf.ZSTitelID	Breast Cancer Research and Treatment	de_DE
dcterms.isPartOf.ZS-Issue	1	de_DE
dcterms.isPartOf.ZS-Volume	182	de_DE
utue.fakultaet	04 Medizinische Fakultät	de_DE